Dr. Mehnert on Promising Biomarkers for Immunotherapy

Janice Mehnert, MD
Published: Monday, Sep 26, 2016


Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discussing promising biomarkers for patients to receive immunotherapy across tumor types.

Across the field, researchers have concluded that PD-L1 expression is important—though it is far from perfect, especially because the various assays available are not standardized, Mehnert explains. Additionally, it is unclear whether it matters more or less in one tumor type versus another.

Researchers should also be studying other factors, such as next-generation sequencing as a surrogate for whole-exome sequencing to identify extreme cases of high mutational load that could be predictive, she adds.

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discussing promising biomarkers for patients to receive immunotherapy across tumor types.

Across the field, researchers have concluded that PD-L1 expression is important—though it is far from perfect, especially because the various assays available are not standardized, Mehnert explains. Additionally, it is unclear whether it matters more or less in one tumor type versus another.

Researchers should also be studying other factors, such as next-generation sequencing as a surrogate for whole-exome sequencing to identify extreme cases of high mutational load that could be predictive, she adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x